We Offer Worldwide Shipping
Login Wishlist

3′,3”’-Binaringenin

$1,152

  • Brand : BIOFRON

  • Catalogue Number : BN-O0938

  • Specification : 98%(HPLC)

  • CAS number : 145399-99-1

  • Formula : C30H22O10

  • Molecular Weight : 542.49

  • PUBCHEM ID : 390361

  • Volume : 5mg

Available on backorder

Quantity
Checkout Bulk Order?

Catalogue Number

BN-O0938

Analysis Method

HPLC,NMR,MS

Specification

98%(HPLC)

Storage

2-8°C

Molecular Weight

542.49

Appearance

Botanical Source

Structure Type

Category

Standards;Natural Pytochemical;API

SMILES

Synonyms

IUPAC Name

(2S,3R)-3-[(2R,3S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-2,3-dihydrochromen-3-yl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one

Density

Solubility

Flash Point

Boiling Point

Melting Point

InChl

InChl Key

WGK Germany

RID/ADR

HS Code Reference

2933990000

Personal Projective Equipment

Correct Usage

For Reference Standard and R&D, Not for Human Use Directly.

Meta Tag

provides coniferyl ferulate(CAS#:145399-99-1) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of coniferyl ferulate are included as well.>> amp version: coniferyl ferulate

No Technical Documents Available For This Product.

PMID

29239131

Abstract

A potential link has been suggested between dispensed finasteride and increased risk of male breast cancer (MBC). Due to the rare occurrence of MBC, it remains to be established if such a relationship exists. The purpose of this study was to combine nationwide registers in four countries to assess the potential association between dispensed finasteride and MBC. A cohort of all males with dispensed finasteride in Denmark, Finland, Norway, and Sweden (1,365,088 person years) was followed up for up to 15 years for breast cancer, and compared to a cohort of males unexposed to finasteride. Individual‐level register data included country, dates of dispensed finasteride, MBC diagnosis, and death. Incidence rate ratios (IRRs) were estimated using a generalized linear model with a Poisson distribution. An increased risk of MBC was found among finasteride users (IRR = 1.44, 95% confidence interval [95% CI] = 1.11-1.88) compared to nonusers. The IRR increased to 1.60 (95% CI = 1.20-2.13) when users in Norway and Sweden with short follow‐up time were excluded. The highest IRR was seen among men with medium duration of dispensed finasteride, medium accumulated consumption of finasteride, and among men with first dispensed finasteride prescription 1-3 years prior to diagnosis. The analyses suggested possible ascertainment bias and did not support a clear relationship between dispensed finasteride and MBC. In conclusion, a significant association between dispensed finasteride and MBC was identified. However, due to limited data for adjustment of potential confounding and surveillance bias in the present study, further research is needed to confirm these results.

KEYWORDS

Breast neoplasms male, finasteride, Nordic countries, pharmacoepidemiology, prostatic neoplasms, registers

Title

Finasteride treatment and male breast cancer: a register‐based cohort study in four Nordic countries

Author

Mathias Meijer, 1 , 2 Lau Caspar Thygesen, 1 Anders Green, 3 , 4 Martha Emneus, 3 Klaus Brasso, 5 Peter Iversen, 5 Eero Pukkala, 6 , 7 Kristian Bolin, 8 , 9 Knut Stavem, 10 , 11 , 12 and Annette K. Ersbøllcorresponding author 1

Publish date

2018 Jan;

PMID

18491403

Abstract

Flavonoids, which are found in certain plant foods, are thought to lower cancer risk through their antioxidant, antiestrogenic and antiproliferative properties. We examined the association of intake of total flavonoids and 7 flavonoid subclasses with risk of lung, colorectal, breast, pancreatic and upper aerodigestive cancer among women in a large prospective cohort study. Study participants were 34,708 postmenopausal women in the Iowa Women’s Health Study who completed a food frequency questionnaire and were followed for cancer occurrence from 1986 through 2004. Flavonoid intake was estimated from 3 databases developed by the USDA Nutrient Data Laboratory (NDL). Hazard ratios (HR) for cancer risk were calculated across total flavonoid and flavonoid subclass intake categories. Interactions between smoking history and flavonoid intake were also examined. After multivariable adjustment, lung cancer incidence was inversely associated with intakes of flavanones (HR = 0.68; 95% CI: 0.53−0.86, all results highest vs. lowest quintile) and proanthocyanidins (HR = 0.75; 95% CI: 0.57−0.97). Among current and past smokers, those with intakes in the highest quintile for flavanones (HR = 0.66; 95% CI: 0.50−0.86), and proanthocyanidins (HR = 0.66; 95% CI; 0.49−0.89) had significantly lower lung cancer incidence than those in the lowest quintile. Similar associations were not seen in never smokers. Isoflavone intake was inversely associated with overall cancer incidence (HR = 0.93, 95% CI: 0.86−1.00). This study provides further support for a beneficial effect of flavonoid intake on lung cancer risk, especially among current and past smokers.

KEYWORDS

flavonoids, lung cancer, colorectal cancer, breast cancer, postmenopausal women

Title

Dietary flavonoid intake and risk of cancer in postmenopausal women: The Iowa Women's Health Study

Author

Gretchen J. Cutler,1 Jennifer A. Nettleton,1 Julie A. Ross,2 Lisa J. Harnack,1,2 David R. Jacobs, Jr.,1,3 Carolyn G. Scrafford,4 Leila M. Barraj,4 Pamela J. Mink,4,5 and Kim Robien1,2,*

Publish date

2009 Aug 1


Description :

Empty ...